80937-25-3

Basic information

• Product Name: 4-(3,4-Dimethoxyphenyl)-4-oxo-2-hydroxybutanoic acid
• Synonyms: 4-(3,4-Dimethoxyphenyl)-4-oxo-2-hydroxybutanoic acid
• CAS NO: 80937-25-3
• Molecular Formula: C₁₂H₁₄O₆
• Molecular Weight: 254.24
• Mol File: 80937-25-3.mol

Chemical Properties

• Boiling Point: 499.4°C at 760 mmHg
• Flash Point: 194.5°C
• Appearance: /
• Density: 1.307g/cm³
• Vapor Pressure: 8.6E-11mmHg at 25°C
• Refractive Index: 1.55
• CAS DataBase Reference: 4-(3,4-Dimethoxyphenyl)-4-oxo-2-hydroxybutanoic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(3,4-Dimethoxyphenyl)-4-oxo-2-hydroxybutanoic acid(80937-25-3)
• EPA Substance Registry System: 4-(3,4-Dimethoxyphenyl)-4-oxo-2-hydroxybutanoic acid(80937-25-3)

Safety Data

• Hazardous Substances Data: 80937-25-3(Hazardous Substances Data)

Usage

InChI:InChI=1/C12H14O6/c1-17-10-4-3-7(5-11(10)18-2)8(13)6-9(14)12(15)16/h3-5,9,14H,6H2,1-2H3,(H,15,16)

Upstream product

• 1131-62-0 1-(3,4-dimethoxyphenyl)ethanone 
• 563-96-2 2,2-dihydroxyacetic acid 

Relevant articles and documents

Gastric anti-secretory, anti-ulcer and cytoprotective properties of substituted (E)-4-phenyl- and heteroaryl-4-oxo-2-butenoic acids

A class of anti-secretory, anti-ulcer and cytoprotective agents, the substituted (E)-4-phenyl and heteroaryl-4-oxo-2-butenoic acids, is described.This chemical structure is not related to those of any known anti-cholinergic drugs, histamine H2-receptor antagonists or prostaglandins.Five compounds, 4-(2-methoxyphenyl)- 15, 4-(4-methoxyphenyl)- 22, 4-(3,4-dimethoxyphenyl)- 32, 4-(3,4,5-trimethoxyphenyl)- 40, and 4-(2-furanyl)-4-oxo-2-butenoic acid 44, have cytoprotective activity at a very low dose (0.6 mg/kg, p.o.) and anti-secretory and anti-ulcer activities at higher doses.One of these compounds, RU 38086 40, has been selected for clinical evaluation.Keywords - anti-ulcer agents / cytoprotective agents / (E)-4-phenyl- and heteroaryl-4-oxo-2-butenoic acids.

Gastro-protecting activity

Diseases and ailments accompanied by gastric and gastroduodenal lesions treated by administering a compound of the formula (I) STR1 in which R represents hydrogen or alkyl containing 1 to 5 carbon atoms and R1 and R2, identical or different, both represent alkoxy containing 1 to 3 carbon atoms, or both represent halogen, or R1 represents hydrogen and R2 represents halogen, nitro or trifluoromethyl, or R1 and R2 form a methylenedioxy group at adjacent carbon atoms, as well as pharmaceutically acceptable salts thereof, particularly alkali metal, alkaline earth metal, or amine salts of said acid.